GlassScriptPhysician profile
Casey Ray Owens
NPI 1437348943
$5,837.07
in general payments reported to CMS, 2019-2025
30 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $321 · 2021: $906 · 2022: $1,018 · 2023: $1,247 · 2024: $1,075 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,306 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,306.39 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,049.06 | 2019-2025 | |
| Janssen Biotech, INC. | $494.28 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $457.51 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.07 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Pfizer INC. | $209.98 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $111.58 | 2024-2025 | Zenpep, Vowst |
| Ardelyx, INC. | $108.57 | 2022-2025 | Ibsrela |
| Celgene Corporation | $97.76 | 2023-2024 | Zeposia |
| Organon LLC | $97.31 | 2021-2025 | Renflexis, Nexplanon, Hadlima |
| Redhill Biopharma INC. | $94.46 | 2022-2024 | Talicia |
| Nestle Healthcare Nutrition INC. | $80.53 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $80.06 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $79.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $78.52 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $70.24 | 2023 | Sucraid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $68.07 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $61.38 | 2022-2025 | Ocaliva |
| Allergan, INC. | $56.83 | 2019-2020 | |
| Braintree Laboratories, INC. | $44.63 | 2021-2024 | Suflave |
| Daiichi Sankyo INC. | $42.53 | 2020 | |
| Merck Sharp & Dohme LLC | $42.31 | 2019-2021 | |
| Mylan Institutional INC. | $40.07 | 2023 | Hulio |
| Ferring Pharmaceuticals INC. | $32.84 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.28 | 2023 | Cyltezo |
| Biocon Biologics INC | $19.44 | 2025 | Yesintek |
| Gilead Sciences, INC. | $18.96 | 2024 | |
| Vivus LLC | $15.40 | 2022 | |
| Sandoz INC. | $14.16 | 2025 | Hyrimoz |
| Ironwood Pharmaceuticals, INC | $13.91 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.28 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.